• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Cancer Immunotherapy

• Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
• Substance-P-mediated immunomodulation of tumor growth in a murine model.
• Cutaneous side-effects of kinase inhibitors and blocking antibodies.
• Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells.
• Rational design of an EGF-IL18 fusion protein: implication for developing tumor therapeutics.
• Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer.
• Randomized phase II designs in cancer clinical trials: current status and future directions.
• Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication.
• The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
• alpha v beta3-dependent cross-presentation of matrix metalloproteinase-2 by melanoma cells gives rise to a new tumor antigen.
• Potent antitumor activity of oncolytic adenovirus expressing mda-7/IL-24 for colorectal cancer.
• The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.
• Phase I trial of intravenous IL-4 pseudomonas exotoxin protein (NBI-3001) in patients with advanced solid tumors that express the IL-4 receptor.
• Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse.
• Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer.
• Autoimmune toxicities associated with the administration of antitumor vaccines and low-dose interleukin-2.
• In vivo hydrodynamic delivery of cDNA encoding IL-2: rapid, sustained redistribution, activation of mouse NK cells, and therapeutic potential in the absence of NKT cells.
• Phenotype and homing of CD4 tumor-specific T cells is modulated by tumor bulk.
• Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro.
• Dendritic cells transduced with tumor-associated antigen gene elicit potent therapeutic antitumor immunity: comparison with immunodominant peptide-pulsed DCs.
• Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer.
• Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma.
• A retrogen plasmid-based vaccine generates high titer antibody responses against the autologous cancer antigen survivin and demonstrates anti-tumor efficacy.
• Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy.
• Introduction of Sd(a) carbohydrate antigen in gastrointestinal cancer cells eliminates selectin ligands and inhibits metastasis.
• Enforced expression of superoxide dismutase 2/manganese superoxide dismutase disrupts autocrine interleukin-6 stimulation in human multiple myeloma cells and enhances dexamethasone-induced apoptosis.
• Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
• Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
• Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft.
• Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
• Cancer prevention with semi-allogeneic ES cell-derived dendritic cells.
• A replication-selective adenoviral vector for head and neck cancers.
• Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals.
• A peptide carrier with a built-in vaccine adjuvant: construction of immunogenic conjugates.
• The potential of phage display virions expressing malignant tumor specific antigen MAGE-A1 epitope in murine model.
• Carbohydrate vaccines as immunotherapy for cancer.
• Tumor-associated carbohydrate antigens: a possible avenue for cancer prevention.
• Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys.
• Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
• Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response.
• The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
• A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy.
• Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
• Herpes simplex virus type-1 amplicon vectors for vaccine generation in acute lymphoblastic leukemia.
• Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies.
• Combination effect of oncolytic adenovirotherapy and TRAIL gene therapy in syngeneic murine breast cancer models.
• Minimally invasive localization of oncolytic herpes simplex viral therapy of metastatic pleural cancer.
• A recombinant IL-4-Pseudomonas exotoxin inhibits protein synthesis and overcomes apoptosis resistance in human CLL B cells.
• Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interleukin-8.
• Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
• Cost-effective manufacture of an allogeneic GM-CSF-secreting breast tumor vaccine in an academic cGMP facility.
• IL-28A and IL-29 mediate antiproliferative and antiviral signals in intestinal epithelial cells and murine CMV infection increases colonic IL-28A expression.
• Comparative activity of Sant7 and anti-IL-6, IL-6R monoclonal antibodies in a murine model of B-cell lymphoma.
• Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
• Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases.
• Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells.
• Suppression of tumor growth in human gastric cancer with HER2 overexpression by an anti-HER2 antibody in a murine model.
• The effects of interleukin-7 on the lymphangiogenic properties of human endothelial cells.
• Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study.
• Phase II randomized study of interleukin-2 with or without 13-cis retinoic acid as maintenance therapy in patients with advanced cancer responsive to chemotherapy.
• IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
• Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes.
• CC chemokine ligand 19 secreted by mature dendritic cells increases naive T cell scanning behavior and their response to rare cognate antigen.
• Immature CD4- CD103+ rat dendritic cells induce rapid caspase-independent apoptosis-like cell death in various tumor and nontumor cells and phagocytose their victims.
• Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways.
• Interferon-alpha plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: a pilot study.
• CD46 plays a key role in tailoring innate immune recognition of apoptotic and necrotic cells.
• Interleukin-21 triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma.
• Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.
• Dendritic cell therapy with interferon-alpha synergistically suppresses outgrowth of established tumors in a murine colorectal cancer model.
• Efficient infection of tumor endothelial cells by a capsid-modified adenovirus.
• A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes.
• Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.
• Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
• Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas.
• Turning on/off tumor-specific CTL response during progressive tumor growth.
• Epigallocatechin-3-gallate impairs chemokine production in human colon epithelial cell lines.
• Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells.
• Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells.
• Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance.
• Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.
• Responses to human CD40 ligand/human interleukin-2 autologous cell vaccine in patients with B-cell chronic lymphocytic leukemia.
• Tid1 negatively regulates the migratory potential of cancer cells by inhibiting the production of interleukin-8.
• Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo.
• Targeted virus replication plus immunotherapy eradicates primary and distant pancreatic tumors in nude mice.
• Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
• A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo.
• A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients.
• Dynamic DNA methylation and histone modifications contribute to lentiviral transgene silencing in murine embryonic carcinoma cells.
• Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
• Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.
• Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma.
• A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
• Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
• Cellular factors influencing Semliki Forest Virus vector biology.
• HSV-1-based amplicon vectors: design and applications.
• Current issues in adeno-associated viral vector production.
• Adenovirus as vehicle for anticancer genetic immunotherapy.
• Biology and application of alphaviruses in gene therapy.
• Development and application of replication-incompetent HSV-1-based vectors.
• DNA vaccination of HSP105 leads to tumor rejection of colorectal cancer and melanoma in mice through activation of both CD4 T cells and CD8 T cells.
• Screening of cytokines to enhance vaccine effects of heat shock protein 70-rich tumor cell lysate.
• A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death.
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
• IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis.
• Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth.
• Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.
• Antibody-based antiangiogenic cancer therapy.
• A new vector for controllable expression of an anti-HER2/neu mini-antibody-barnase fusion protein in HEK 293T cells.
• A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
• Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade.
• Autologous transplantation of CD133 selected hematopoietic progenitor cells for treatment of relapsed acute lymphoblastic leukemia.
• Membrane HSP70: the molecule triggering gammadelta T cells in the early stage of tumorigenesis.
• Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer.
• Re-targeting of cytotoxic T lymphocytes and/or natural killer cells to CEA-expressing tumor cells with anti-CEA antibody activity.
• IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients.
• Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells.
• A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes.
• Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231.
• Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated.
• Lentiviral vector expression of tumour antigens in dendritic cells as an immunotherapeutic strategy.
• Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.
• Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients.
• Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection.
• Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
• Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
• Target ability and therapy efficacy of immunoliposomes using a humanized antihepatoma disulfide-stabilized Fv fragment on tumor cells.
• In vitro uptake of gelatin nanoparticles by murine dendritic cells and their intracellular localisation.
• Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice.
• Generation of antigen-presenting cells using cultured dendritic cells and amplified autologous tumor mRNA.
• Immunohistochemical detection of CD 95 (Fas) & Fas ligand (Fas-L) in plasma cells of multiple myeloma and its correlation with survival.
• Enhanced targeting and killing of tumor cells expressing the CXC chemokine receptor 4 by transducible anticancer peptides.
• Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
• Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine.
• Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
• Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
• FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma.
• Combination B7-Fc fusion protein treatment and Treg cell depletion therapy.
• Supernatural T cells: genetic modification of T cells for cancer therapy.
• Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
• Characterization of the gammadelta T cell response to acute leukemia.
• CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.
• Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34(+) progenitor-derived dendritic cells.
• CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia.
• Identification of the pentapeptide constituting a dominant epitope common to all eukaryotic heat shock protein 90 molecular chaperones.
• Erythropoietin attenuates cachectic events and decreases production of interleukin-6, a cachexia-inducing cytokine.
• A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis.
• A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model.
• VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.
• Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.
• Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients.
• Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.
• Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells.
• Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival.
• Th2-dominated antitumor immunity induced by DNA immunization with the genes coding for a basal core peptide PDTRP and GM-CSF.
• The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.
• The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.
• A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer.
• In vivo targeting of dendritic cells for activation of cellular immunity using vaccine carriers based on pH-responsive microparticles.
• Up-regulation of beta-catenin by a viral oncogene correlates with inhibition of the seven in absentia homolog 1 in B lymphoma cells.
• A new way to generate cytolytic tumor-specific T cells: electroporation of RNA coding for a T cell receptor into T lymphocytes.
• In vivo electrogene transfer of interleukin-12 inhibits tumor growth and lymph node and lung metastases in mouse mammary carcinomas.
• Prostate tumor cells infected with a recombinant influenza virus expressing a truncated NS1 protein activate cytolytic CD8+ cells to recognize noninfected tumor cells.
• Crystal structure of human T cell leukemia virus protease, a novel target for anticancer drug design.
• Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.
• Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
• Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
• Treatment of NSCLC patients with an EGF-based cancer vaccine: report of a Phase I trial.
• AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
• Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
• Therapeutic effect of alpha-galactosylceramide-loaded dendritic cells genetically engineered to express SLC/CCL21 along with tumor antigen against peritoneally disseminated tumor cells.
• Phase I study of radioimmunotherapy with an anti-CD20 murine radioimmunoconjugate ((90)Y-ibritumomab tiuxetan) in relapsed or refractory indolent B-cell lymphoma.
• A novel strategy to compensate the disadvantages of live vaccine using suicide-gene system and provide better antitumor immunity.
• Therapy-related lymphomas in patients with autoimmune diseases after treatment with disease-modifying anti-rheumatic drugs.
• Telomerase-specific T-cells kill pancreatic tumor cells in vitro and in vivo.
• Inhibition of host signal transducer and activator of transcription factor 6 results in cure with cyclophosphamide and interleukin 12 immunotherapy.
• Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab.
• Human tumor membrane vesicles modified to express glycolipid-anchored IL-12 by protein transfer induce T cell proliferation in vitro: a potential approach for local delivery of cytokines during vaccination.
• Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center.
• Mechanisms of trastuzumab resistance and their clinical implications.
• In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition.
• HSP-10 in ovarian cancer: expression and suppression of T-cell signaling.
• Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation.
• Aberrant T helper cell response in tumor-bearing mice limits the efficacy of dendritic cell vaccine.
• Late expression of nitroreductase in an oncolytic adenovirus sensitizes colon cancer cells to the prodrug CB1954.
• A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.
• Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells.
• Statins and cancer risk: a meta-analysis.
• mHFE7A, a newly identified monoclonal antibody to Fas, induces apoptosis in human melanoma cells in vitro and delays the growth of melanoma xenotransplants.
• Breaking tolerance to tumors with dendritic cell-based immunotherapy.
• Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma.
• Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
• Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy.
• CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
• Interleukin-17 receptor-like gene is a novel antiapoptotic gene highly expressed in androgen-independent prostate cancer.
• In vivo imaging of adenovirus transduction and enhanced therapeutic efficacy of combination therapy with conditionally replicating adenovirus and adenovirus-p27.
• Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells.
• IFN-beta is a highly potent inhibitor of gastroenteropancreatic neuroendocrine tumor cell growth in vitro.
• Tumor-derived interleukin-4 reduces tumor clearance and deviates the cytokine and granzyme profile of tumor-induced CD8+ T cells.
• Pancreatic cancer cells invasiveness is mainly affected by interleukin-1beta not by transforming growth factor-beta1.
• Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma.
• Using anti-VEGF McAb and magnetic nanoparticles as double-targeting vector for the radioimmunotherapy of liver cancer.
• The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling.
• The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro.
• Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.
• Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
• Glycoprotein A34, a novel target for antibody-based cancer immunotherapy.
• A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.
• Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
• Effect of interleukin-18 on metastasis of mouse osteosarcoma cells.
• The anti-tumor efficacy of a GM-CSF-secreting tumor cell vaccine is not inhibited by docetaxel administration.
• Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520.
• Direct targeting of genetically modified tumour cells to Fc gammaRI triggers potent tumour cytotoxicity.
• In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma.
• Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
• Effect of adenovirus-mediated heat shock protein expression and oncolysis in combination with low-dose cyclophosphamide treatment on antitumor immune responses.
• Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
• The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
• Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses.
• Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors.
• Vaccine with beta-defensin 2-transduced leukemic cells activates innate and adaptive immunity to elicit potent antileukemia responses.
• Antitumor efficacy of a urokinase activation-dependent anthrax toxin.
• Antitumor efficacy of CD137 ligation is maximized by the use of a CD137 single-chain Fv-expressing whole-cell tumor vaccine compared with CD137-specific monoclonal antibody infusion.
• Synergistic effects of combined therapy using paclitaxel and [90Y-DOTA]776.1 on growth of OVCAR-3 ovarian carcinoma xenografts.
• Selective migration of neuralized embryonic stem cells to stem cell factor and media conditioned by glioma cell lines.
• Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma.
• Autoimmunity and tumor immunity induced by immune responses to mutations in self.
• A novel dendritic cell subset involved in tumor immunosurveillance.
• IL-4 inhibits the TNF-alpha induced proliferation of renal cell carcinoma (RCC) and cooperates with TNF-alpha to induce apoptotic and cytokine responses by RCC: implications for antitumor immune responses.
• Development of the PANVAC-VF vaccine for pancreatic cancer.
• Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors.
• Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
• Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
• Resistance of cancers to immunologic cytotoxicity and adoptive immunotherapy via X-linked inhibitor of apoptosis protein expression and coexisting defects in mitochondrial death signaling.
• The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice.
• Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors.
• Optimal organization of a polypeptide-based candidate cancer vaccine composed of cryptic tumor peptides with enhanced immunogenicity.
• Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
• Synthesis and biological evaluation of alpha-galactosylceramide (KRN7000) and isoglobotrihexosylceramide (iGb3).
• Interferon-induced sensitization to apoptosis is associated with repressed transcriptional activity of the hTERT promoter in multiple myeloma.
• T lymphocytes as potential therapeutic drug carrier for cancer treatment.
• Anti-tumor effect and mechanism of SEA-Fab' coupled protein on gastric tumor.
• Disruption of T cell regulatory pathways is necessary for immunotherapeutic cure of T cell acute lymphoblastic leukemia in mice.
• Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein.
• Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
• Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy.
• Antitumor resistance activation in mice: can the immunological memory cells enhance resistance?
• Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.
• Cytidine-phosphate-guanosine oligodeoxynucleotides and interferon-alpha-expressing tumor cells effectively induce dendritic cell maturation in vitro.
• Biodistribution and localization of iodine-131-labeled metuximab in patients with hepatocellular carcinoma.
• Administration of PUMA adenovirus increases the sensitivity of esophageal cancer cells to anticancer drugs.
• Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
• A human cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM overexpressing tumor cells.
• Oncolysis and suppression of tumor growth by a GFP-expressing oncolytic adenovirus controlled by an hTERT and CMV hybrid promoter.
• Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.
• Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
• The role of interleukin 1 in growth and metastasis of human cancer xenografts.
• Antitumor effects of systemic and local immunization with a CTL-directed peptide in combination with a local injection of OK-432.
• Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer.
• Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
• Preparation and evaluation of unimolecular pentavalent and hexavalent antigenic constructs targeting prostate and breast cancer: a synthetic route to anticancer vaccine candidates.
• Are shorter courses of filgrastim prophylaxis associated with increased risk of hospitalization?
• Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies.
• Immune gene-viral therapy with triplex efficacy mediated by oncolytic adenovirus carrying an interferon-gamma gene yields efficient antitumor activity in immunodeficient and immunocompetent mice.
• Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
• Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
• Effects of rate, volume, and dose of intratumoral infusion on virus dissemination in local gene delivery.
• Restriction of adenoviral replication to the transcriptional intersection of two different promoters for colorectal and pancreatic cancer treatment.
• Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer.
• Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma.
• The role of human papillomavirus in squamous carcinoma of the head and neck.
• Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.
• Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.
• Inflammatory chemokines in cancer growth and progression.
• Cancer CXC chemokine networks and tumour angiogenesis.
• Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma.
• Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA.
• Gene therapy of ovarian cancer with IFN-alpha-producing fibroblasts: comparison of constitutive and inducible vectors.
• A randomized phase II trial of interleukin-2 in combination with four different doses of bryostatin-1 in patients with renal cell carcinoma.
• Immunotherapy for prostate cancer.
• Development and characterization of interleukin-18-loaded biodegradable microspheres.
• Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.
• Synergistic antitumor effects of immune cell-viral biotherapy.
• Characterization of the recombinant adenovirus vector AdYB-1: implications for oncolytic vector development.
• G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
• Adenoviral gene transfer of stromal cell-derived factor-1 to murine tumors induces the accumulation of dendritic cells and suppresses tumor growth.
• Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
• Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine.
• Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade).
• TLR3 can directly trigger apoptosis in human cancer cells.
• Novel immunostimulatory agent based on CpG oligodeoxynucleotide linked to the nontoxic B subunit of cholera toxin.
• Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype.
• Construction and characterization of a novel fusion protein consisting of anti-CD3 antibody fused to recombinant interleukin-2.
• Development of a "reverse capture" autoantibody microarray for studies of antigen-autoantibody profiling.
• A monoclonal antibody against CD148, a receptor-like tyrosine phosphatase, inhibits endothelial-cell growth and angiogenesis.
• CCL19 reduces tumour burden in a model of advanced lung cancer.
• Increase of CD4+ CD25+ regulatory T-cells in the liver of patients with hepatocellular carcinoma.
• B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.
• Interleukin-2 gene-encoded stromal cells inhibit the growth of metastatic cholangiocarcinomas.
• Doxorubicin-conjugated anti-midkine monoclonal antibody as a potential anti-tumor drug.
• Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy.
• TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility.
• Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.
• Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.
• Thymosin alpha1 suppresses proliferation and induces apoptosis in human leukemia cell lines.
• Ionizing radiation enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human ovarian cancer.
• Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector.
• Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors.
• Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
• Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
• Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
• Inhibition of experimental metastasis by targeting the HUIV26 cryptic epitope in collagen.
• Targeting melanoma cells with human high molecular weight-melanoma associated antigen-specific antibodies elicited by a peptide mimotope: functional effects.
• Defective adhesion in tumor infiltrating CD8+ T cells.
• Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
• IL-21 enhances tumor-specific CTL induction by anti-DR5 antibody therapy.
• Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus.
• Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion.
• Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses.
• Immune enhancement and anti-tumour activity of IL-23.
• DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method.
• Cancer immunomics: using autoantibody signatures in the early detection of prostate cancer.
• Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer.
• Eradication of established tumors in mice by a combination antibody-based therapy.
• Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
• Transferable anticancer innate immunity in spontaneous regression/complete resistance mice.
• Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
• Phase I trial of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma.
• Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.
• Evaluating strategies to enhance the anti-tumor immune response to a carbohydrate mimetic peptide vaccine.
• Specific immune recognition of pancreatic carcinoma by patient-derived CD4 and CD8 T cells and its improvement by interferon-gamma.
• Estrogen enhances the efficacy of an oncolytic HSV-1 mutant in the treatment of estrogen receptor-positive breast cancer.
• Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.
• Neutralization of interleukin-2 retards the growth of mouse renal cancer.
• IL-23 promotes tumour incidence and growth.
• A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
• Virology- and immunology-based gene therapy for cancer.
• Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner.
• A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors.
• Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells.
• Combination cancer therapy by hapten-targeted prodrug-activating enzymes and cytokines.
• A rapid and efficient in vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of cancer.
• Doxorubicin plus interleukin-2 chemoimmunotherapy against breast cancer in mice.
• Therapeutic efficacy of antigen-specific vaccination and toll-like receptor stimulation against established transplanted and autochthonous melanoma in mice.
• Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
• Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
• Infectivity-enhanced adenoviruses deliver efficacy in clinical samples and orthotopic models of disseminated gastric cancer.
• Stimulation through CD40 on mouse and human renal cell carcinomas triggers cytokine production, leukocyte recruitment, and antitumor responses that can be independent of host CD40 expression.
• Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer.
• Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.
• Oncolytic adenoviral vector carrying the cytosine deaminase gene for melanoma gene therapy.
• Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.
• PEGylated J591 mAb loaded in PLGA-PEG-PLGA tri-block copolymer for targeted delivery: in vitro evaluation in human prostate cancer cells.
• Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy.
• Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.
• Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
• Antitumor therapeutic effects of e7 subunit and DNA vaccines in an animal cervical cancer model: antitumor efficacy of e7 therapeutic vaccines is dependent on tumor sizes, vaccine doses, and vaccine delivery routes.
• Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1beta and hypoxia in small cell lung cancer.
• In vitro and in vivo evaluation of 111In-labeled E. coli heat-stable enterotoxin analogs for specific targeting of human breast cancers.
• Tumor cyclooxygenase-2 gene suppresses local immune responses in patients with hepatocellular carcinoma.
• Oncolytic measles virus targets high CD46 expression on multiple myeloma cells.
• A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy.
• Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses.
• Natural killer T cell-mediated antitumor immune responses and their clinical applications.
• New target therapies in advanced pancreatic cancer.
• Antibody arrays: technical considerations and clinical applications in cancer.
• Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
• Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells.
• TMV-peptide fusion vaccines induce cell-mediated immune responses and tumor protection in two murine models.
• Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo.
• Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer.
• A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients.
• Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
• Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.
• A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma.
• Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma.
• High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells.
• Acacetin suppressed LPS-induced up-expression of iNOS and COX-2 in murine macrophages and TPA-induced tumor promotion in mice.
• Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
• Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.
• IFN-gamma and T-bet expression in human dendritic cells from normal donors and cancer patients is controlled through mechanisms involving ERK-1/2-dependent and IL-12-independent pathways.
• Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene.
• Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
• Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice.
• Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists.
• Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
• E1B55K-deleted adenovirus (ONYX-015) overrides G1/S and G2/M checkpoints and causes mitotic catastrophe and endoreduplication in p53-proficient normal cells.
• Manufacturing and quality control of cell-based tumor vaccines: a scientific and a regulatory perspective.
• Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
• ReGel polymer-based delivery of interleukin-2 as a cancer treatment.
• Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
• Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma.
• BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
• Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.
• Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models.
• Synthesis and evaluation of some lipidic aminoalcohols and diamines as immunomodulators.
• Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
• Bispecific antibody pretargeting of tumor neovasculature for improved systemic radiotherapy of solid tumors.
• Identification of class I MHC-associated phosphopeptides as targets for cancer immunotherapy.
• The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR.
• Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.
• Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference.
• Vector prime/protein boost vaccine that overcomes defects acquired during aging and cancer.
• Effective anti-angiogenic therapy of established tumors in mice by naked anti-human endoglin (CD105) antibody: differences in growth rate and therapeutic response between tumors growing at different sites.
• The CXCR5 chemokine receptor is expressed by carcinoma cells and promotes growth of colon carcinoma in the liver.
• Targeting the lymphotoxin-beta receptor with agonist antibodies as a potential cancer therapy.
• In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3.
• A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
• Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model.
• Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.
• Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis.
• Cooperative effects of adenoviral vector-mediated interleukin 12 gene therapy with radiotherapy in a preclinical model of metastatic prostate cancer.
• Conversion of a tumor-binding peptide identified by phage display to a functional chimeric T cell antigen receptor.
• A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
• Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
• Synthesis of glycosylated human tumor necrosis factor alpha coupled with N-acetylneuraminic acid.
• Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy.
• A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
• Identification of a series of highly potent activators of the Nurr1 signaling pathway.
• Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.
• A urokinase-activated recombinant anthrax toxin is selectively cytotoxic to many human tumor cell types.
• Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
• Triggering CD40 on endothelial cells contributes to tumor growth.
• Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
• Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
• Relaxin expression from tumor-targeting adenoviruses and its intratumoral spread, apoptosis induction, and efficacy.
• The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.
• Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.
• CD4+CD25+ regulatory T-cell-inactivation in combination with adenovirus vaccines enhances T-cell responses and protects mice from tumor challenge.
• Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions.
• Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
• A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
• A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
• A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo.
• The use of a tropism-modified measles virus in folate receptor-targeted virotherapy of ovarian cancer.
• Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo.
• Colony-stimulating factors: clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia.
• Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.
• Phase II study of lenalidomide in patients with metastatic renal cell carcinoma.
• Expression of MHC I and NK ligands on human CD133+ glioma cells: possible targets of immunotherapy.
• Neurospheres enriched in cancer stem-like cells are highly effective in eliciting a dendritic cell-mediated immune response against malignant gliomas.
• Distinct roles for IFN regulatory factor (IRF)-3 and IRF-7 in the activation of antitumor properties of human macrophages.
• Eradication of tumor colonization and invasion by a B cell-specific immunotoxin in a murine model for human primary intraocular lymphoma.
• CD4+ T cells in the absence of the CD8+ cytotoxic T cells are critical and sufficient for NKT cell-dependent tumor rejection.
• Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
• CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients.
• Human adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.
• Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
• A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
• Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
• Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
• In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
• Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.
• Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment.
• Adenoviral-mediated interferon alpha overcomes resistance to the interferon protein in various cancer types and has marked bystander effects.
• In vitro anti-tumor immune response induced by dendritic cells transfected with hTERT recombinant adenovirus.
• A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma.
• Exogenous wt-p53 enhances the antitumor effect of HSV-TK/GCV on C6 glioma cells.
• A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
• Tumor antigen-based immunotherapy and immunoprevention of cancer.
• Tissue inhibitor of metalloproteinases-2 improves antitumor efficacy of a replicating adenovirus in vivo.
• Phase I, open-label, dose-escalating study of a genetically engineered herpes simplex virus, NV1020, in subjects with metastatic colorectal carcinoma to the liver.
• Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
• Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
• Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases.
• Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody.
• CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
• c7E3 Fab inhibits human tumor angiogenesis in a SCID mouse human skin xenograft model.
• Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy.
• Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
• Macrophages regulate the angiogenic switch in a mouse model of breast cancer.
• IL-22-mediated tumor growth reduction correlates with inhibition of ERK1/2 and AKT phosphorylation and induction of cell cycle arrest in the G2-M phase.
• Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
• In vitro co-stimulation of anti-tumor activity by soluble B7 molecules.
• Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells.
• The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
• A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
• Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
• A novel HSV-1 virus, JS1/34.5-/47-, purges contaminating breast cancer cells from bone marrow.
• The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells.
• A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies.
• Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
• Direct vaccination with pseudotype baculovirus expressing murine telomerase induces anti-tumor immunity comparable with RNA-electroporated dendritic cells in a murine glioma model.
• Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.
• Highly efficient and carcinoma-specific adenoviral replication restricted by the EGP-2 promoter.
• Adenovirus-mediated expression of tissue factor pathway inhibitor-2 inhibits endothelial cell migration and angiogenesis.
• Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.
• TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines.
• Macrophage-targeted photosensitizer conjugate delivered by intratumoral injection.
• Complete antitumor protection by perioperative immunization with GM3/VSSP vaccine in a preclinical mouse melanoma model.
• Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.
• Oncolytic HSV-1 for the treatment of brain tumours.
• Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies.
• Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner.
• Bifunctional ligands that target cells displaying the alpha v beta3 integrin.
• An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
• Macrophages are essential for antitumour effects against weakly immunogenic murine tumours induced by class B CpG-oligodeoxynucleotides.
• Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy.
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
• Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin.
• Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme.
• Inhibition of BCL11B expression leads to apoptosis of malignant but not normal mature T cells.
• Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity.
• Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
• A low-dose combination therapy of interleukin-2 and interferon-alpha is effective for lung metastasis of renal cell carcinoma: a multicenter open study.
• N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.
• A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
• Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model.
• Intrahepatic delivery of alpha-galactosylceramide-pulsed dendritic cells suppresses liver tumor.
• Immunogenic gangliosides in human ovarian carcinoma.
• Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
• CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models.
• A fully human chimeric immune receptor for retargeting T-cells to CEA-expressing tumor cells.
• Differential tumor cell targeting of anti-HER2 (Herceptin) and anti-CD20 (Mabthera) coupled nanoparticles.
• Recombinant interleukin-2 significantly augments activity of rituximab in human tumor xenograft models of B-cell non-Hodgkin lymphoma.
• Emerging role of platelet-derived growth factor receptor-beta inhibition in radioimmunotherapy of experimental pancreatic cancer.
• Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma.
• Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatin-treated tumors to CTL-mediated killing in therapeutic synergy.
• Combretastatin A-4-phosphate effectively increases tumor retention of the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down.
• The immunosuppressant FTY720 inhibits tumor angiogenesis via the sphingosine 1-phosphate receptor 1.
• Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials.
• Gene transfer of the CD40-ligand to human dendritic cells induces NK-mediated antitumor effects against human carcinoma cells.
• Intracellular route and mechanism of action of ERB-hRNase, a human anti-ErbB2 anticancer immunoagent.
• Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
• Induced sensitization of tumor stroma leads to eradication of established cancer by T cells.
• Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
• Murine dendritic cells modified with CXCL10 gene and tumour cell lysate mediate potent antitumour immune responses in mice.
• Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial.
• Selectively oncolytic mutant of HSV-1 lyses HeLa cells mediated by Ras/RTN3.
• Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes.
• Bortezomib disrupts tumour-dendritic cell interactions in myeloma and lymphoma: therapeutic implications.
• Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
• Incorporation of CpG oligonucleotide ligand into protein-loaded particle vaccines promotes antigen-specific CD8 T-cell immunity.
• Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
• A CD46-binding Chimpanzee Adenovirus Vector as a Vaccine Carrier.
• Five-year Follow-up of Trial of Replication-competent Adenovirus-mediated Suicide Gene Therapy for Treatment of Prostate Cancer.
• Cell-penetrating autoantibody induces caspase-mediated apoptosis through catalytic hydrolysis of DNA.
• Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions.
• Adenovirus-mediated expression of a dominant negative Ku70 fragment radiosensitizes human tumor cells under aerobic and hypoxic conditions.
• Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
• Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.
• An infectious retrovirus susceptible to an IFN antiviral pathway from human prostate tumors.
• Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer.
• mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft.
• VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth.
• A three-dimensional assay for measurement of viral-induced oncolysis.
• Enhanced T-cell immunity induced by dendritic cells with phagocytosis of heat shock protein 70 gene-transfected tumor cells in early phase of apoptosis.
• Incorporation of a laminin-derived peptide (SIKVAV) on polymer-modified adenovirus permits tumor-specific targeting via alpha6-integrins.
• Complete remission of multiple myeloma after autoimmune hemolytic anemia: possible association with interferon-alpha.
• A phase I trial of hyperthermia-induced interleukin-12 gene therapy in spontaneously arising feline soft tissue sarcomas.
• Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
• Engineering oncolytic measles virus to circumvent the intracellular innate immune response.
• Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
• Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
• A new epitope peptide derived from hepatitis C virus 1b possessing the capacity to induce cytotoxic T-lymphocytes in HCV1b-infected patients with HLA-A11, -A31, and -A33.
• Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
• A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
• Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor.
• Adenovirus 5 vector genetically re-targeted by an Affibody molecule with specificity for tumor antigen HER2/neu.
• Adoptive therapy of head and neck squamous cell carcinoma with antibody coated immune cells: a pilot clinical trial.
• Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer.
• A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment.
• Depleting intratumoral CD4+CD25+ regulatory T cells via FasL protein transfer enhances the therapeutic efficacy of adoptive T cell transfer.
• Modulation of telomerase promoter tumor selectivity in the context of oncolytic adenoviruses.
• Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.
• A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.
• Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.
• Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
• Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer.
• A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy.
• A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing.
• An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer.
• Inhibition of prostate carcinogenesis by combined active immunoprophylaxis.
• The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: a double-blind placebo-controlled prospective phase III study by Radiation Therapy Oncology Group 9901.
• Intratumoral injection of dendritic cells in combination with local hyperthermia induces systemic antitumor effect in patients with advanced melanoma.
• Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models.
• Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes.
• Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas.
• Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model.
• Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells.
• Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.
• Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression.
• Antibody-mediated p53 protein therapy prevents liver metastasis in vivo.
• Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer.
• An interferon alpha2 mutant optimized by phage display for IFNAR1 binding confers specifically enhanced antitumor activities.
• Small-molecule Bcl-2 inhibitors sensitise tumour cells to immune-mediated destruction.
• Influence of heat stress on human monocyte-derived dendritic cell functions with immunotherapeutic potential for antitumor vaccines.
• Virus-specific CD8+ T cells in the liver: armed and ready to kill.
• Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice.
• Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta.
• Immunotherapy of tumors with neuroimmune ligand capsaicin.
• Recombinant IL-7 enhances the potency of GM-CSF-secreting tumor cell immunotherapy.
• Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.
• Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.
• Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation.
• Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group.
• Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
• Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells.
• Novel recombinant adenoviral vector that targets the interleukin-13 receptor alpha2 chain permits effective gene transfer to malignant glioma.
• Mannan-mediated gene delivery for cancer immunotherapy.
• Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy.
• The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer.
• Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.
• Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
• Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
• Tumor cells expressing anti-CD137 scFv induce a tumor-destructive environment.
• Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck.
• Induction of tumor-specific T-cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors.
• Virosome-mediated delivery of tumor antigen to plasmacytoid dendritic cells.
• Anti-Cripto Mab inhibit tumour growth and overcome MDR in a human leukaemia MDR cell line by inhibition of Akt and activation of JNK/SAPK and bad death pathways.
• Development and characterization of novel photosensitizer : scFv conjugates for use in photodynamic therapy of cancer.
• Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
• Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha.
• Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
• Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6-positive metastatic breast cancer: final results of a phase I study.
• VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model.
• Role for CD47-SIRPalpha signaling in xenograft rejection by macrophages.
• Endogenous IL-12 triggers an antiangiogenic program in melanoma cells.
• A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors.
• Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies.
• Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
• A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
• Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis.
• A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients.
• Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming.
• Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus.
• Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma.
• CTLA-4 expressed by chemoresistant, as well as untreated, myeloid leukaemia cells can be targeted with ligands to induce apoptosis.
• Delivery of antigen to CD40 induces protective immune responses against tumors.
• Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance.
• Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines.
• Defective antitumor responses in CX3CR1-deficient mice.
• TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
• Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
• Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer.
• Luciferase imaging for evaluation of oncolytic adenovirus replication in vivo.
• CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
• Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia.
• Improving tumor targeting and therapeutic potential of Salmonella VNP20009 by displaying cell surface CEA-specific antibodies.
• Phase I evaluation of a fully human anti-alphav integrin monoclonal antibody (CNTO 95) in patients with advanced solid tumors.
• IL-28 elicits antitumor responses against murine fibrosarcoma.
• Tumor-released microvesicles as vehicles of immunosuppression.
• Effect of human skin-derived stem cells on vessel architecture, tumor growth, and tumor invasion in brain tumor animal models.
• IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.
• Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
• Therapeutic effect of pEgr-IL18-B7.2 gene radiotherapy in B16 melanoma-bearing mice.
• Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells.
• New peptide vaccine candidates for epithelial cancer patients with HLA-A3 supertype alleles.
• The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells.
• A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients With Resected Pancreatic Adenocarcinoma.
• Flt3-L gene therapy enhances immunocytokine-mediated antitumor effects and induces long-term memory.
• Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model.
• Co-application of ricin A chain and a recombinant adenovirus expressing ricin B chain as a novel approach for cancer therapy.
• Cytotoxic T lymphocyte response induced by an improved synthetic lipopeptide vaccine against cervical cancer.
• Targeting CD37+ lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
• CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.
• Evaluation of cancer virotherapy with attenuated replicative Semliki forest virus in different rodent tumor models.
• An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
• Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer.
• Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group.
• Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model.
• Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
• Chemical glycosylation in the synthesis of glycoconjugate antitumour vaccines.
• A novel pretargeting method for measuring antibody internalization in tumor cells.
• An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.
• Locoregional IL-2 therapy in the treatment of colon cancer. Cell-induced lesions of a murine model.
• Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
• Dendritic cell-based full-length survivin vaccine in treatment of experimental tumors.
• In vitro antitumoral activity of baculovirus-expressed chimeric recombinant anti-CD4 antibody 13B8.2 on T-cell lymphomas.
• Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin.
• Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.
• Inhibition of angiogenesis and tumor metastasis by targeting a matrix immobilized cryptic extracellular matrix epitope in laminin.
• Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice.
• Interferon gamma Stimulates Cellular Maturation of Dendritic Cell Line DC2.4 Leading to Induction of Efficient Cytotoxic T Cell Responses and Antitumor Immunity.
• A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group.
• Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy.
• Long-circulating poly(ethylene glycol)-coated emulsions to target solid tumors.
• A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.
• Oral delivery of tumor-targeting Salmonella for cancer therapy in murine tumor models.
• Phase I study with an autologous tumor cell vaccine for locally advanced or metastatic prostate cancer.
• Poly(D,L-Lactic-Co-Glycolic Acid) microsphere delivery of adenovirus for vaccination.
• Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice.
• Radiolabeled high affinity peptidomimetic antagonist selectively targets alpha(v)beta(3) receptor-positive tumor in mice.
• Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia.
• Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity.
• Meta analysis of advanced cancer survival data using lognormal parametric fitting: a statistical method to identify effective treatment protocols.
• Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21.
• E1A, E1B Double-Restricted Adenovirus with RGD-Fiber Modification Exhibits Enhanced Oncolysis for CAR-Deficient Biliary Cancers.
• Increasing Anticarcinoma Activity of an Anti-erbB2 Recombinant Immunotoxin by the Addition of an Anti-EpCAM sFv.
• Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
• Endostatin plus interferon-alpha2b therapy for metastatic melanoma: a novel combination of antiangiogenic and immunomodulatory agents.
• Increased Sensitivity of Radiated Murine Cervical Cancer Tumors to E7 Subunit Vaccine-driven CTL-mediated Killing Induces Synergistic Anti-tumor Activity.
• Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain.
• Targeting of humanized antibody D93 to sites of angiogenesis and tumor growth by binding to multiple epitopes on denatured collagens.
• CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease.
• Antitumor effects of imidazoquinolines in urothelial cell carcinoma of the bladder.
• Expansion of CD4(+)CD25(+) suppressive regulatory T cells from rhesus macaque peripheral blood by FN18/antihuman CD28-coated Dynal beads.
• Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies.
• Scavenger receptor-a-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.
• Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin a.
• Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models.
• The Antibody-Mediated Targeted Delivery of Interleukin-15 and GM-CSF to the Tumor Neovasculature Inhibits Tumor Growth and Metastasis.
• Scavenger receptor-a negatively regulates antitumor immunity.
• Enhanced delivery of immunoliposomes to human dendritic cells by targeting the multilectin receptor DEC-205.
• The C-terminal pentapeptide of LHRH is a dominant B cell epitope with antigenic and biological function.
• CD4+CD25+ T Regulatory Cells Dominate Multiple Immune Evasion Mechanisms in Early but Not Late Phases of Tumor Development in a B Cell Lymphoma Model.
• Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients.
• Allogeneic retrovirally transduced, IL-2- and IFN-gamma-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial.
• A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
• N-Acetyl-d-glucosamine substituted calix[4]arenes as stimulators of NK cell-mediated antitumor immune response.
• Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming.
• Local and distant immune-mediated control of colon cancer growth with fusogenic membrane glycoproteins in combination with viral oncolysis.
• Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model.
• Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines.
• Characterisation and radioimmunotherapy of L19-SIP, an anti-angiogenic antibody against the extra domain B of fibronectin, in colorectal tumour models.
• Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys.
• Anti-tumor activity of cationic liposomes conjugated adenovirus containing CCL19 gene.
• Mice with enhanced macrophage Angiotensin-converting enzyme are resistant to melanoma.
• Immunohistochemical Evaluation of H-R3 a Novel Humanized Monoclonal Antibody That Neutralizes the EGF-receptor.
• 'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'.
• Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
• Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
• Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
• Phase I Trial of BAY 50-4798, an Interleukin-2-Specific Agonist in Advanced Melanoma and Renal Cancer.
• In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas.
• Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors.
• Systemic Administration of IL-23 Induces Potent Antitumor Immunity Primarily Mediated through Th1-Type Response in Association with the Endogenously Expressed IL-12.
• Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma.
• Anti-tumor effects of immunotherapeutic peptide on the treatment of hepatocellular carcinoma with HBc carrier.
• Characterization of novel murine anti-CD20 monoclonal antibodies and their comparison to 2B8 and c2B8 (rituximab).
• Fast-tracked CTL: Rapid induction of potent anti-tumor killer T cells in situ.
• Susceptibility of cancer cells to herpes simplex virus-dependent apoptosis.
• Combination of the oncolytic adenovirus ICOVIR-5 with chemotherapy provides enhanced anti-glioma effect in vivo.
• Intratumoral injection of IL-12 plasmid DNA - results of a phase I/IB clinical trial.
• Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer.
• Local Expression of SLC Deliveryed by Adeno-associated Virus Within the Tumor Bed Stimulates Strong Anti-liver Tumor Immunity.
• Monoclonal Antibodies to Six-Transmembrane Epithelial Antigen of the Prostate-1 Inhibit Intercellular Communication In vitro and Growth of Human Tumor Xenografts In vivo.
• The discovery of carboline analogs as potent MAPKAP-K2 inhibitors.
• Phase II Study of Capecitabine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines or Taxanes.
• Peptide vaccines of the her-2/neu dimerization loop are effective in inhibiting mammary tumor growth in vivo.
• Targeted Inflammation During Oncolytic Virus Therapy Severely Compromises Tumor Blood Flow.
• Induction of urokinase-type plasminogen activator, interleukin-8 and early growth response-1 by STI571 through activating mitogen activated protein kinase in human small cell lung cancer cells.
• Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes.
• Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma.
• Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome.
• Pre-clinical Evaluation of a CEA DNA Prime/protein Boost Vaccination Strategy Against Colorectal Cancer.
• Enhancing antitumor immunity: combining IL-12 with TGFbeta1 antagonism.
• Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model.
• Cyclin-dependent kinaselike 5 is a novel target of immunotherapy in adult T-cell leukemia.
• Rapid generation of CMV pp65-specific T cells for immunotherapy.
• In situ tumor vaccination with adenovirus vectors encoding measles virus fusogenic membrane proteins and cytokines.
• Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer: our long-term clinical experience (GOIM study).
• Panitumumab a novel drug in cancer treatment.
• Cloning and characterization of an adenoviral vector for highly efficient and doxycycline - suppressible expression of bioactive human single - chain interleukin 12 in colon cancer.
• Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12.
• Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
• Gene therapy with CX3CL1/Fractalkine induces antitumor immunity to regress effectively mouse hepatocellular carcinoma.
• An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
• Tumor immunotherapy using bone marrow-derived dendritic cells overexpressing Toll-like receptor adaptors.
• Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase Peptide.
• A phase-I trial of the epidermal growth factor receptor directed bispecific antibody MDX-447 without and with recombinant human granulocyte-colony stimulating factor in patients with advanced solid tumors.
• Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation.
• Synthesis of Glycocluster-Tumor Antigenic Peptide Conjugates for Dendritic Cell Targeting.
• The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection.
• Hyaluronic Acid-Paclitaxel: Antitumor Efficacy against CD44(+) Human Ovarian Carcinoma Xenografts.
• Human Mesenchymal Stem Cells Lack Tumor Tropism but Enhance the Antitumor Activity of Oncolytic Adenoviruses in Orthotopic Lung and Breast Tumors.
• Effective Relief of Malignant Ascites in Patients with Advanced Ovarian Cancer by a Trifunctional Anti-EpCAM x Anti-CD3 Antibody: A Phase I/II Study.
• Bevacizumab-Induced Transient Remodeling of the Vasculature in Neuroblastoma Xenografts Results in Improved Delivery and Efficacy of Systemically Administered Chemotherapy.
• A Vascular Endothelial Growth Factor Receptor-2 Inhibitor Enhances Antitumor Immunity through an Immune-Based Mechanism.
• A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses.
• Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy.
• The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.
• IL-6-Encoding Tumor Antigen Generates Potent Cancer Immunotherapy Through Antigen Processing and Anti-apoptotic Pathways.
• Enhanced In Vivo Antitumor Efficacy of Poorly Soluble PDT Agent, Meso-Tetraphenylporphine, in PEG-PE-Based Tumor-Targeted Immunomicelles.
• Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus.
• Effect of a novel fully human monovalent antigen-bindin